Peter Rahmer - 30 Jun 2025 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role
Chief Corporate Develpment Officer
Signature
/s/ Brian Adams, as Attorney-in-Fact
Issuer symbol
RLAY
Transactions as of
30 Jun 2025
Net transactions value
+$14,700
Form type
4
Filing time
01 Jul 2025, 17:00:16 UTC
Previous filing
30 Apr 2025
Next filing
30 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Rahmer Peter Chief Corporate Develpment Officer C/O RELAY THERAPEUTICS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE /s/ Brian Adams, as Attorney-in-Fact 01 Jul 2025 0001959229

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLAY Common Stock Award $14,700 +5,000 +1.3% $2.94 395,081 30 Jun 2025 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction.
F2 In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2025.
F3 Includes 204,715 shares underlying RSUs.

Remarks:

Chief Corporate Develpment Officer